Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary efficacy of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((90)Y-J591) in patients with androgen-independent prostate cancer (PC).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Clin Oncol

Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Publisher: American Society of Clinical Oncology (ASCO)

ISSN: 0732-183X

ISSN (Print): 0732-183X

Publication date (Electronic): Jul 01 2004

Volume: 22

Issue: 13

Affiliations

[1 ] Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA.

Article

Publisher Item ID: JCO.2004.09.154

DOI: 10.1200/JCO.2004.09.154

PubMed ID: 15173215

SO-VID: 8b64b8ce-03a6-4afb-be1a-6a2dade3b798

History

Data availability:

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.